Index RUT
P/E 14.90
EPS (ttm) 1.55
Insider Own 0.83%
Shs Outstand 41.37M
Perf Week 2.99%
Market Cap 881.89M
Forward P/E 9.54
EPS next Y 2.42
Insider Trans -25.75%
Shs Float 37.89M
Perf Month 2.44%
Income 65.80M
PEG 0.62
EPS next Q 0.36
Inst Own 107.45%
Short Float 5.64%
Perf Quarter 6.26%
Sales 434.00M
P/S 2.03
EPS this Y 14.61%
Inst Trans -0.29%
Short Ratio 7.54
Perf Half Y 40.90%
Book/sh 0.97
P/B 23.75
EPS next Y 18.63%
ROA 11.64%
Short Interest 2.14M
Perf Year -1.07%
Cash/sh 3.86
P/C 5.97
EPS next 5Y 24.20%
ROE 707.53%
52W Range 15.23 - 23.63
Perf YTD 20.46%
Dividend Est. 0.04 (0.17%)
P/FCF 14.55
EPS past 5Y 4.14%
ROI 17.40%
52W High -2.33%
Beta 1.54
Dividend TTM 0.04 (0.17%)
Quick Ratio -
Sales past 5Y -11.76%
Gross Margin 95.37%
52W Low 51.59%
ATR (14) 0.45
Dividend Ex-Date Mar 14, 2024
Current Ratio -
EPS Y/Y TTM -33.80%
Oper. Margin 26.64%
RSI (14) 55.80
Volatility 1.81% 1.73%
Employees 387
Debt/Eq 8.61
Sales Y/Y TTM 2.94%
Profit Margin 15.16%
Recom 2.33
Target Price 24.00
Option/Short Yes / Yes
LT Debt/Eq 8.41
EPS Q/Q -24.47%
Payout 2.59%
Rel Volume 0.48
Prev Close 23.51
Sales Surprise 5.73%
EPS Surprise 30.51%
Sales Q/Q 7.71%
Earnings May 02 BMO
Avg Volume 283.65K
Price 23.08
SMA20 1.19%
SMA50 2.12%
SMA200 14.37%
Trades
Volume 135,444
Change -1.83%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-14-21 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Oct-29-21 Downgrade
Keefe Bruyette
Outperform → Mkt Perform
$31 → $32
Apr-09-21 Upgrade
BofA Securities
Neutral → Buy
$22 → $27
Apr-08-21 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$21 → $30
Jul-29-20 Upgrade
BofA Securities
Underperform → Neutral
$12 → $16
Jul-28-20 Upgrade
Keefe Bruyette
Mkt Perform → Outperform
$14 → $18.50
May-12-20 Upgrade
Morgan Stanley
Underweight → Equal-Weight
$25
Apr-08-20 Downgrade
Morgan Stanley
Equal-Weight → Underweight
Apr-06-20 Downgrade
Keefe Bruyette
Outperform → Mkt Perform
$7.25
Jan-02-20 Downgrade
Wells Fargo
Overweight → Equal Weight
$11
May-03-19 Downgrade
Evercore ISI
Outperform → In-line
$14 → $15
Apr-12-19 Downgrade
BofA/Merrill
Buy → Underperform
Jan-14-19 Downgrade
Citigroup
Buy → Neutral
Jan-09-19 Downgrade
Keefe Bruyette
Outperform → Mkt Perform
Apr-30-18 Upgrade
Sandler O'Neill
Hold → Buy
Show Previous Ratings
Apr-18-24 12:00PM
Apr-10-24 08:30AM
Apr-02-24 09:40AM
Mar-20-24 09:40AM
Mar-15-24 09:40AM
09:40AM
Loading…
Feb-28-24 09:40AM
Feb-15-24 11:35PM
Feb-14-24 09:55AM
Feb-02-24 08:44AM
12:28AM
(Thomson Reuters StreetEvents)
Feb-01-24 01:12PM
08:15AM
07:21AM
(Associated Press Finance)
07:00AM
Jan-25-24 10:00AM
10:54AM
Loading…
Jan-22-24 10:54AM
Jan-10-24 08:30AM
Dec-22-23 09:40AM
Dec-06-23 09:40AM
Dec-05-23 01:02PM
Nov-05-23 01:39PM
Nov-02-23 07:57AM
(Associated Press Finance)
07:30AM
Oct-31-23 07:15AM
Oct-30-23 10:00AM
Oct-26-23 10:02AM
Oct-06-23 08:30AM
Aug-10-23 01:08PM
Aug-03-23 11:56PM
(Thomson Reuters StreetEvents) -5.21%
09:05AM
08:02AM
Loading…
08:02AM
(Associated Press Finance)
07:45AM
Jul-26-23 08:25AM
Jul-13-23 08:16AM
05:45AM
Jun-21-23 08:00PM
Jun-05-23 08:34AM
May-31-23 09:40AM
May-29-23 12:00PM
May-04-23 08:35AM
07:28AM
07:04AM
Apr-27-23 10:03AM
Apr-26-23 08:00PM
Apr-20-23 05:25PM
Apr-17-23 09:15AM
Apr-13-23 08:30AM
Apr-02-23 09:56AM
Mar-23-23 09:40AM
Feb-16-23 12:00PM
09:40AM
Feb-06-23 02:06AM
Feb-02-23 08:35AM
07:13AM
Jan-26-23 06:55PM
10:01AM
Jan-24-23 12:00PM
Jan-23-23 06:55AM
Jan-13-23 08:30AM
Dec-13-22 07:16PM
Nov-09-22 05:36AM
Nov-03-22 09:35AM
07:30AM
Oct-28-22 10:00AM
Oct-27-22 05:55PM
10:02AM
Oct-23-22 10:56AM
Oct-17-22 08:30AM
Oct-10-22 07:26AM
Jul-28-22 09:05AM
07:30AM
Jul-13-22 09:02AM
Jul-11-22 08:30AM
Jun-21-22 02:40AM
May-16-22 08:19AM
May-08-22 08:27AM
May-06-22 08:54AM
04:52AM
May-05-22 08:35AM
08:29AM
08:28AM
07:15AM
Apr-28-22 03:02PM
09:35AM
Apr-15-22 12:00PM
Apr-14-22 08:30AM
Feb-07-22 03:28PM
Feb-04-22 12:00PM
Feb-03-22 05:38PM
08:35AM
07:15AM
Jan-28-22 01:38PM
Jan-21-22 05:05AM
Jan-18-22 04:06PM
Jan-10-22 08:30AM
Jan-06-22 10:00AM
08:30AM
Dec-31-21 08:41AM
Dec-27-21 05:41AM
Dec-24-21 11:38PM
BrightSphere Investment Group, Inc. is a holding company, which engages in the provision of asset management services. It operates through the Quant and Solutions segment. The Quant and Solutions segment involves leveraging data and technology in a computational, factor-based investment process across a range of asset classes and geographies, including Global, non-U.S., emerging markets, and managed volatility equities, as well as multi-asset products. The company was founded in 1980 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hart Richard Jonathan Chief Legal Officer Feb 15 '24 Option Exercise 0.00 11,815 0 73,477 Feb 20 04:19 PM Wiater Christina PFO / PAO Feb 15 '24 Option Exercise 0.00 1,353 0 15,864 Feb 20 04:11 PM Rana Suren President and CEO Feb 14 '24 Sale 20.74 109,960 2,280,361 130,967 Feb 15 04:35 PM Rana Suren President and CEO Feb 13 '24 Option Exercise 12.00 414,000 4,968,000 544,967 Feb 15 04:35 PM Trebbi Barbara Director Jun 07 '23 Option Exercise 0.00 4,762 0 36,646 Jun 09 06:12 PM Paulson John Director Jun 07 '23 Option Exercise 0.00 8,334 0 8,334 Jun 09 06:18 PM Chersi Robert J Director Jun 07 '23 Option Exercise 0.00 4,762 0 19,170 Jun 09 06:08 PM
Index -
P/E -
EPS (ttm) -1.62
Insider Own 2.41%
Shs Outstand 365.24M
Perf Week -1.15%
Market Cap 3.13B
Forward P/E 2.09
EPS next Y 4.10
Insider Trans -0.07%
Shs Float 356.59M
Perf Month -9.70%
Income -592.00M
PEG -
EPS next Q 0.69
Inst Own 79.14%
Short Float 6.31%
Perf Quarter 6.47%
Sales 8.76B
P/S 0.36
EPS this Y 12.75%
Inst Trans 19.20%
Short Ratio 8.04
Perf Half Y 21.59%
Book/sh -2.80
P/B -
EPS next Y 4.68%
ROA -2.23%
Short Interest 22.50M
Perf Year 13.23%
Cash/sh 2.63
P/C 3.25
EPS next 5Y 2.60%
ROE -
52W Range 5.57 - 11.46
Perf YTD 6.73%
Dividend Est. -
P/FCF 4.04
EPS past 5Y 32.76%
ROI -2.81%
52W High -25.31%
Beta 0.90
Dividend TTM -
Quick Ratio 0.94
Sales past 5Y 1.03%
Gross Margin 58.48%
52W Low 53.67%
ATR (14) 0.42
Dividend Ex-Date Aug 30, 2010
Current Ratio 1.30
EPS Y/Y TTM -160.23%
Oper. Margin 18.34%
RSI (14) 38.16
Volatility 3.03% 5.52%
Employees 20270
Debt/Eq -
Sales Y/Y TTM 7.79%
Profit Margin -6.76%
Recom 2.86
Target Price 10.17
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 90.57%
Payout -
Rel Volume 0.70
Prev Close 8.53
Sales Surprise 4.99%
EPS Surprise -4.77%
Sales Q/Q 9.80%
Earnings May 02 BMO
Avg Volume 2.80M
Price 8.56
SMA20 -8.92%
SMA50 -7.44%
SMA200 3.08%
Trades
Volume 1,965,922
Change 0.35%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-20-23 Upgrade
Jefferies
Hold → Buy
$9 → $16
Jun-16-23 Downgrade
TD Cowen
Outperform → Market Perform
Jul-29-22 Downgrade
Truist
Buy → Hold
Jul-29-22 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$12 → $5
Jul-28-22 Downgrade
JP Morgan
Overweight → Neutral
Jun-13-22 Resumed
JP Morgan
Overweight
$12
Mar-24-21 Downgrade
BofA Securities
Neutral → Underperform
$27
Feb-17-21 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$26 → $42
Jan-22-21 Downgrade
Piper Sandler
Overweight → Neutral
$25 → $30
Sep-17-20 Upgrade
BofA Securities
Underperform → Neutral
$19
Aug-24-20 Reiterated
H.C. Wainwright
Buy
$64 → $50
Aug-24-20 Reiterated
H.C. Wainwright
Buy
$50 → $64
Jun-17-20 Reiterated
H.C. Wainwright
Buy
$50 → $64
Apr-24-20 Initiated
Citigroup
Buy
$30
Apr-02-20 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Jan-29-20 Downgrade
Wolfe Research
Outperform → Peer Perform
Jan-22-20 Upgrade
Wells Fargo
Underweight → Equal Weight
$32
Dec-12-19 Upgrade
JP Morgan
Neutral → Overweight
$32 → $38
Dec-02-19 Initiated
Goldman
Neutral
Oct-25-19 Initiated
Cowen
Outperform
$35
Show Previous Ratings
Apr-23-24 12:04PM
Apr-22-24 12:41PM
Apr-20-24 09:16AM
Apr-11-24 04:22PM
01:03PM
12:40PM
Loading…
12:40PM
12:10PM
11:17AM
11:03AM
08:00AM
Apr-08-24 05:33PM
01:27PM
Apr-05-24 06:15PM
Apr-03-24 12:05PM
09:50AM
08:00AM
Loading…
08:00AM
Apr-02-24 08:00AM
Mar-28-24 02:19PM
05:23AM
Mar-15-24 09:50AM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
Mar-01-24 08:00AM
Feb-27-24 03:27AM
Feb-23-24 12:25PM
11:53AM
Feb-22-24 11:30AM
10:03AM
09:30AM
08:25AM
07:33AM
Loading…
07:33AM
07:33AM
(Associated Press Finance)
07:00AM
Feb-21-24 12:10PM
07:26AM
(Associated Press Finance)
Feb-19-24 09:15AM
Feb-15-24 10:00AM
Feb-12-24 08:00AM
Feb-08-24 10:59AM
Feb-07-24 12:00PM
Feb-01-24 04:10PM
08:00AM
Jan-31-24 04:00PM
Jan-30-24 05:54PM
08:00AM
Jan-18-24 04:50PM
08:00AM
Jan-08-24 11:15AM
Dec-22-23 10:23AM
Dec-21-23 07:00AM
Dec-18-23 09:40AM
08:00AM
Dec-13-23 07:43AM
Dec-11-23 09:55AM
Dec-05-23 08:00AM
Nov-30-23 09:40AM
Nov-24-23 09:55AM
Nov-13-23 09:55AM
Nov-10-23 12:42PM
08:00AM
Nov-08-23 08:00AM
Nov-03-23 02:03PM
12:47PM
Nov-02-23 04:13PM
11:00AM
09:41AM
(Associated Press Finance)
08:34AM
07:00AM
Nov-01-23 12:22PM
10:43AM
10:40AM
09:30AM
07:07AM
(Associated Press Finance)
Oct-31-23 02:58AM
Oct-30-23 04:35PM
Oct-26-23 10:02AM
10:02AM
08:00AM
Oct-25-23 10:02AM
Oct-20-23 05:20PM
Oct-17-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-04-23 08:00AM
Sep-29-23 10:15AM
Sep-26-23 08:54AM
Sep-21-23 11:16AM
08:00AM
Sep-20-23 11:25AM
10:50AM
Sep-19-23 04:32PM
02:37PM
01:46PM
11:47AM
Sep-18-23 05:45PM
Sep-15-23 08:25AM
Sep-12-23 08:00AM
Sep-11-23 04:04PM
09:04AM
08:00AM
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Carson Seana EVP, General Counsel Mar 04 '24 Sale 9.80 6,313 61,867 499,905 Mar 04 04:16 PM Carson Seana EVP, General Counsel Dec 05 '23 Sale 7.38 220 1,624 382,925 Dec 05 04:35 PM Carson Seana EVP, General Counsel Nov 06 '23 Sale 7.61 43 327 384,836 Nov 06 05:06 PM Carson Seana EVP, General Counsel Sep 06 '23 Sale 8.28 6,685 55,352 385,213 Sep 06 04:33 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite